Hepion Pharmaceuticals: Funding, Investors & Team (Oct 2026)
A biopharmaceutical business called Hepion Pharmaceuticals (Nasdaq: HEPA) focuses on the creation of pleiotropic pharmacological therapies for the management of chronic liver disease. With non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases, this therapy strategy targets fibrosis and hepatocellular carcinoma (HCC). We are developing CRV431 as a cyclophilin inhibitor to address these various complicated diseases. Multiple metabolic pathways implicated in the development of liver disease are targeted by CRV431. In NASH model preclinical investigations, CRV431 consistently reduced liver fibrosis, inflammation, and malignant tumors. Additionally, CRV431 exhibits antiviral action against the viruses that cause liver illness such as hepatitis B, C, and D. Due to CRV431's several methods of action, there are numerous therapeutic options for reducing the potentially fatal dangers of liver disease.
Hepion Pharmaceuticals has raised $20.0M across 1 funding round on record, the most recent an undisclosed round of $20.0M announced in Nov 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hepion Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Hepion Pharmaceuticals Funding Rounds
Hepion Pharmaceuticals Founders and Leadership Team
Contact details for the Hepion Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Hepion Pharmaceuticals Funding Compared to Other Biotechnology Startups
Hepion Pharmaceuticals' latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hepion Pharmaceuticals in Biotechnology and Edison
Companies Similar to Hepion Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Hepion Pharmaceuticals Funding FAQs
What does Hepion Pharmaceuticals do?
A biopharmaceutical business called Hepion Pharmaceuticals (Nasdaq: HEPA) focuses on the creation of pleiotropic pharmacological therapies for the management of chronic liver disease. With non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases, this therapy strategy targets fibrosis and hepatocellular carcinoma (HCC). We are developing CRV431 as a cyclophilin inhibitor to address these various complicated diseases. Multiple metabolic pathways implicated in the development of liver disease are targeted by CRV431. In NASH model preclinical investigations, CRV431 consistently reduced liver fibrosis, inflammation, and malignant tumors. Additionally, CRV431 exhibits antiviral action against the viruses that cause liver illness such as hepatitis B, C, and D. Due to CRV431's several methods of action, there are numerous therapeutic options for reducing the potentially fatal dangers of liver disease.
How much funding has Hepion Pharmaceuticals raised?
Hepion Pharmaceuticals has raised $20.0M across 1 round on record. The most recent is an undisclosed round of $20.0M announced in Nov 2022.
When did Hepion Pharmaceuticals last raise funding?
Hepion Pharmaceuticals' most recent funding round on record is an undisclosed round of $20.0M, announced in Nov 2022.
Who is the CEO of Hepion Pharmaceuticals?
Gary Jacob is listed as CEO at Hepion Pharmaceuticals.
Where is Hepion Pharmaceuticals headquartered?
Hepion Pharmaceuticals is based in Edison, New Jersey, United States.
How many employees does Hepion Pharmaceuticals have?
Hepion Pharmaceuticals is in the 11-50 employee band.
How does Hepion Pharmaceuticals' funding compare to other Biotechnology startups?
Hepion Pharmaceuticals' latest round of $20.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Hepion Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hepion Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.